Emanuel Raschi

7.0k total citations · 3 hit papers
169 papers, 4.1k citations indexed

About

Emanuel Raschi is a scholar working on Toxicology, Cardiology and Cardiovascular Medicine and Pharmacology. According to data from OpenAlex, Emanuel Raschi has authored 169 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Toxicology, 35 papers in Cardiology and Cardiovascular Medicine and 26 papers in Pharmacology. Recurrent topics in Emanuel Raschi's work include Pharmacovigilance and Adverse Drug Reactions (46 papers), Drug-Induced Adverse Reactions (16 papers) and Diabetes Treatment and Management (15 papers). Emanuel Raschi is often cited by papers focused on Pharmacovigilance and Adverse Drug Reactions (46 papers), Drug-Induced Adverse Reactions (16 papers) and Diabetes Treatment and Management (15 papers). Emanuel Raschi collaborates with scholars based in Italy, United States and France. Emanuel Raschi's co-authors include Fabrizio De Ponti, Elisabetta Poluzzi, Ugo Moretti, Milo Gatti, Michele Fusaroli, Valentina Vasina, Andrea Ardizzoni, Carlo Piccinni, Giulio Marchesini and Francesco Salvo and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and PLoS ONE.

In The Last Decade

Emanuel Raschi

165 papers receiving 4.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems

2024 66 citations Elisabetta Poluzzi, Ugo Moretti et al. SHILAP Revista de lepidopterología profile →
Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality

2024 44 citations Georgios Schoretsanitis, Stefan Weiler et al. JAMA Network Open profile →
Cardiovascular therapeutic targets of sodium-glucose co-transporter 2 (SGLT2) inhibitors beyond heart failure

2025 26 citations Emanuel Raschi et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Emanuel Raschi	851	659	636	608	566	169	4.1k
Elisabetta Poluzzi	1.4k 1.7×	513 0.8×	1.2k 2.0×	557 0.9×	606 1.1×	158	5.1k
Annalisa Capuano	635 0.7×	821 1.2×	1.1k 1.8×	566 0.9×	657 1.2×	266	5.8k
David J. Graham	1.6k 1.8×	244 0.4×	654 1.0×	396 0.7×	867 1.5×	115	5.6k
Concetta Rafaniello	265 0.3×	438 0.7×	394 0.6×	252 0.4×	286 0.5×	98	2.2k
Xavier Vidal	590 0.7×	227 0.3×	281 0.4×	280 0.5×	813 1.4×	123	4.9k
Sebastian Harder	1.0k 1.2×	422 0.6×	402 0.6×	210 0.3×	304 0.5×	109	3.5k
Michelle Whirl‐Carrillo	480 0.6×	1.5k 2.3×	2.4k 3.7×	142 0.2×	1.3k 2.3×	103	9.3k
Diane K. Wysowski	496 0.6×	374 0.6×	630 1.0×	331 0.5×	207 0.4×	49	3.8k
Janice B. Schwartz	1.7k 2.0×	409 0.6×	2.6k 4.1×	89 0.1×	488 0.9×	146	7.7k
Renke Maas	2.9k 3.4×	311 0.5×	908 1.4×	132 0.2×	302 0.5×	156	6.7k

Countries citing papers authored by Emanuel Raschi

Since Specialization

Citations

This map shows the geographic impact of Emanuel Raschi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emanuel Raschi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emanuel Raschi more than expected).

Fields of papers citing papers by Emanuel Raschi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emanuel Raschi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emanuel Raschi. The network helps show where Emanuel Raschi may publish in the future.

Co-authorship network of co-authors of Emanuel Raschi

This figure shows the co-authorship network connecting the top 25 collaborators of Emanuel Raschi. A scholar is included among the top collaborators of Emanuel Raschi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emanuel Raschi. Emanuel Raschi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Poluzzi, Elisabetta, et al.. (2025). Disproportionality analysis on semaglutide and nonarteritic anterior ischemic optic neuropathy in the FDA adverse event reporting system: An emerging pharmacovigilance signal?. Obesity Research & Clinical Practice. 19(2). 178–180. 6 indexed citations

Plaça, M. La, et al.. (2025). Benefit-Risk Assessment of GLP-1 Receptor Agonists: Implications for Dermatologists and Plastic Surgeons. Dermatology and Therapy. 15(11). 3173–3193. 1 indexed citations

Starace, Michela, et al.. (2024). Symmetrical cutaneous rash in two women. SHILAP Revista de lepidopterología. 12(5). e8877–e8877. 1 indexed citations

Schoretsanitis, Georgios, Stefan Weiler, Corrado Barbui, Emanuel Raschi, & Chiara Gastaldon. (2024). Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality. JAMA Network Open. 7(8). e2423385–e2423385. 44 indexed citations breakdown →

Fusaroli, Michele, Francesco Salvo, Charles Khouri, & Emanuel Raschi. (2024). The reporting of disproportionality analysis in pharmacovigilance: spotlight on the READUS-PV guideline. Frontiers in Pharmacology. 15. 1488725–1488725. 7 indexed citations

Goldman, Adam, Emanuel Raschi, Amit Druyan, et al.. (2024). Gastrointestinal Perforations Associated With JAK Inhibitors: A Disproportionality Analysis of the FDA Adverse Event Reporting System. United European Gastroenterology Journal. 13(4). 566–575. 3 indexed citations

Fusaroli, Michele, Charles Khouri, Elisabetta Poluzzi, et al.. (2024). Meta-analyzing Results From Disproportionality Analysis of Individual Case Safety Reports. Journal of Clinical Psychopharmacology. 44(4). 443–444. 2 indexed citations

Fusaroli, Michele, Arndis Simonsen, Stephanie A. Borrie, et al.. (2023). Identifying Medications Underlying Communication Atypicalities in Psychotic and Affective Disorders: A Pharmacovigilance Study Within the FDA Adverse Event Reporting System. Journal of Speech Language and Hearing Research. 66(9). 3242–3259. 7 indexed citations

Gelsomino, Francesco, Rita Rinaldi, Lorenzo Muccioli, et al.. (2023). Peripheral nervous system adverse events associated with immune checkpoint inhibitors. Journal of Neurology. 270(6). 2975–2986. 28 indexed citations

10.

Crescioli, Giada, Valentina Maggini, Emanuel Raschi, et al.. (2023). Suspected adverse reactions to medications and food supplements containing Serenoa repens: A worldwide analysis of pharmacovigilance and phytovigilance spontaneous reports. Phytotherapy Research. 37(11). 5289–5299. 2 indexed citations

11.

Gastaldon, Chiara, Elena Arzenton, Emanuel Raschi, et al.. (2023). Pharmacovigilance analysis of the Vigibase on neonatal withdrawal syndrome following in utero exposure to antidepressants. European Psychiatry. 66(S1). S96–S96.

12.

Goldman, Adam, Emanuel Raschi, Joab Chapman, et al.. (2022). Progressive multifocal leukoencephalopathy in patients treated with chimeric antigen receptor T cells. Blood. 141(6). 673–677. 8 indexed citations

13.

Goldman, Adam, Emanuel Raschi, Tali Cukierman‐Yaffe, et al.. (2021). Hyperglycaemic disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study. European Journal of Preventive Cardiology. 29(9). 1334–1342. 25 indexed citations

14.

Fusaroli, Michele, Emanuel Raschi, Manuela Contin, et al.. (2021). Impulsive conditions in Parkinson's disease: A pharmacosurveillance-supported list. Parkinsonism & Related Disorders. 90. 79–83. 7 indexed citations

15.

Lunghi, Carlotta, et al.. (2020). Prevalence and Determinants of Long-Term Utilization of Antidepressant Drugs: A Retrospective Cohort Study. SHILAP Revista de lepidopterología.

16.

Mathieu, Clément, M Arnaud, Emanuel Raschi, et al.. (2020). Risk of bradyarrhythmia related to ticagrelor: A systematic review and meta-analysis. Pharmacological Research. 160. 105089–105089. 3 indexed citations

17.

Fadini, Gian Paolo, Mayur Sarangdhar, Fabrizio De Ponti, Angelo Avogaro, & Emanuel Raschi. (2019). Pharmacovigilance assessment of the association between Fournier’s gangrene and other severe genital adverse events with SGLT-2 inhibitors. BMJ Open Diabetes Research & Care. 7(1). e000725–e000725. 31 indexed citations

18.

Antonazzo, Ippazio Cosimo, Carlo Piccinni, Emanuel Raschi, et al.. (2019). Long-acting injectable antipsychotics: Six-month follow-up of new outpatient treatments in Bologna Community Mental Health Centres. PLoS ONE. 14(2). e0211938–e0211938. 3 indexed citations

19.

Raschi, Emanuel, Anna Girardi, Elisabetta Poluzzi, et al.. (2018). Adverse Events to Food Supplements Containing Red Yeast Rice: Comparative Analysis of FAERS and CAERS Reporting Systems. Drug Safety. 41(8). 745–752. 24 indexed citations

20.

Godman, Brian, Max Petzold, Kathleen Bennett, et al.. (2014). Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications. BMC Medicine. 12(1). 98–98. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact